Followers | 251 |
Posts | 50099 |
Boards Moderated | 46 |
Alias Born | 08/29/2007 |
Thursday, February 15, 2024 4:39:34 AM
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent GRI News
- GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase • GlobeNewswire Inc. • 05/14/2024 01:05:00 PM
- GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/13/2024 12:00:00 PM
- GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity • GlobeNewswire Inc. • 04/29/2024 12:45:00 PM
- GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar • GlobeNewswire Inc. • 04/25/2024 01:15:00 PM
- GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent • GlobeNewswire Inc. • 04/16/2024 12:35:00 PM
- GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference • GlobeNewswire Inc. • 04/08/2024 12:35:00 PM
- GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 04/01/2024 11:35:00 AM
- GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference • GlobeNewswire Inc. • 03/28/2024 01:00:00 PM
- GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators • GlobeNewswire Inc. • 03/14/2024 12:45:00 PM
- GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom • GlobeNewswire Inc. • 03/04/2024 01:30:00 PM
- GRI Bio Announces Pricing of $5.5 Million Public Offering • GlobeNewswire Inc. • 02/02/2024 01:00:00 PM
- GRI Bio Announces Reverse Stock Split • GlobeNewswire Inc. • 01/26/2024 01:05:00 PM
- GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”) • GlobeNewswire Inc. • 12/05/2023 02:05:00 PM
- GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”) • GlobeNewswire Inc. • 11/27/2023 01:35:00 PM
- GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/15/2023 01:05:00 PM
- GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases • GlobeNewswire Inc. • 10/31/2023 12:45:00 PM
- GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference • GlobeNewswire Inc. • 10/19/2023 12:45:00 PM
- GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression • GlobeNewswire Inc. • 10/17/2023 12:35:00 PM
- GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference • GlobeNewswire Inc. • 10/11/2023 01:05:00 PM
- GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions • GlobeNewswire Inc. • 10/05/2023 12:45:00 PM
- GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/06/2023 01:05:00 PM
- GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR • GlobeNewswire Inc. • 08/23/2023 01:00:00 PM
- GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/14/2023 12:05:00 PM
- GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models • GlobeNewswire Inc. • 08/07/2023 12:35:00 PM
- GRI Bio (NASDAQ: GRI) to Present at Benzinga’s Virtual Biotech Conference • GlobeNewswire Inc. • 08/03/2023 12:30:00 PM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONG • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM